Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EFGARTIGIMOD ALFA vs ELACESTRANT: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

EFGARTIGIMOD ALFA vs ELACESTRANT: Safety Overview

Metric EFGARTIGIMOD ALFA ELACESTRANT
Total FAERS Reports 249 6,935
Deaths Reported 26 525
Death Rate 10.4% 7.6%
Hospitalizations 115 843
Average Patient Age 54.0 yrs 65.7 yrs
% Female Patients 82.5% 99.1%
FDA Approval Date N/A Jan 27, 2023
Manufacturer argenx US Stemline Therapeutics, Inc.
Route INTRAVENOUS ORAL
Marketing Status Prescription Prescription